Atyr Pharma Stock News

aTyr Pharma (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr []

The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an

The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an

aTyr Pharma, Inc. (NASDAQ:LIFE) Analysts at Oppenheimer raised their FY2025 earnings per share (EPS) estimates for aTyr Pharma in a research report issued to clients and investors on Thursday, November 11th. Oppenheimer analyst H. Singh now forecasts that the biotechnology company will post earnings per share of $0.22 for the year, up from their []

Equities research analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to post sales of $6.75 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for aTyr Pharmas earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $10.00 million. aTyr Pharma posted sales of []

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2021 Results - Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 20.75% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pat

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

Atyr Pharma (LIFE) stock is soaring higher on Tuesday after the company released positive data from a recent clinical trial. The post LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares S

aTyr Pharma Inc (NASDAQ: LIFE) is trading significantly higher Tuesday after multiple analyst firms maintained bullish ratings on the stock and raised their respective price targets following the com